Granted Patent B2

US 12,208,099 · App. 17/275,178 · Granted Jan 28, 2025

Inventors: Ruth Wei Aranda (San Diego, CA); James Gail Christensen (San Diego, CA); Lars Daniel Engstrom (Carlsbad, CA); Jill Hallin (San Diego, CA); Peter Olson (San Diego, CA)

Assignee: Mirati Therapeutics, Inc.

A61K31/519A61K31/428A61K31/4375A61K31/44A61K31/4985A61K31/506A61K31/517A61K31/5377A61K45/06A61P35/00

Abstract

Claims (12)

1. A method of treating non-small cell lung cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 1) Raf family kinase inhibitor Lifirafenib (BGB-283) and 2) a KRAS G12C inhibitor of formula:

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the therapeutically effective amount of the combination of the Raf family kinase inhibitor and the KRAS G12C inhibitor results in an increased duration of overall survival, an increased duration of progression free survival, an increase in tumor growth regression, an increase in tumor growth inhibition or an increased duration of stable disease in the subjects relative to treatment with only the KRas G12C inhibitor.

3. The method according to claim 1 , wherein the therapeutically effective amount of the KRas G12C inhibitor in the combination is between about 0.01 to 100 mg/kg per day.

4. A method according to claim 1 , wherein the Raf family kinase inhibitor synergistically increases the sensitivity of non-small cell lung cancer cells to the KRas G12C inhibitor.

5. A method for increasing the sensitivity of a non-small cell lung cancer cell to a KRas G12C inhibitor compound according to claim 1 comprising administering to a subject with a non-small cell lung cancer undergoing KRas G12C treatment with a compound of claim 1 or a pharmaceutically acceptable salt thereof, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, a therapeutically effective amount of a Raf family kinase inhibitor, wherein the Raf family kinase inhibitor synergistically increases the sensitivity of the non-small cell lung cancer cell to the KRas G12C inhibitor.

6. A method for inhibiting KRas G12C activity in a non-small cell lung cancer cell, comprising contacting the non-small cell lung cancer cell in which inhibition of KRas G12C activity is desired with an effective amount of 1) a Raf family kinase inhibitor Lifirafenib (BGB-283) and 2) a KRas G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof, wherein the Raf family kinase inhibitor synergistically increases the sensitivity of the non-small cell lung cancer cell to the KRas G12C inhibitor.

7. A pharmaceutical composition, comprising a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRas G12C inhibitor according to claim 1 , and a pharmaceutically acceptable excipient.

8. A kit comprising the pharmaceutical composition of claim 7 for treating KRas G12C non-small cell lung cancer in a subject.

9. A kit comprising: a) a pharmaceutical composition comprising a Raf family kinase inhibitor Lifirafenib (BGB-283) and b) a pharmaceutical composition comprising a KRas G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof for treating a KRas G12C non-small cell lung cancer in a subject.

Assignments (1)

Continuity (2)

References Cited (375)

Cited By (6)

US 12,466,840 US 12,479,834 US 12,630,559 US 12,643,885 US 12,673,041 US 12,702,658